110 related articles for article (PubMed ID: 7249249)
1. Maintenance management of acute nonlymphocytic leukemia.
Lewis JP; Pajak TF; Linman JW; Bateman JR
Cancer Clin Trials; 1981; 4(2):115-24. PubMed ID: 7249249
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of remission in adult acute nonlymphoblastic leukemia using intermittent courses of cytosine arabinoside (NSC-63878) and 6-thioguanine (NSC-752).
Armitage JO; Burns CP
Cancer Treat Rep; 1976 May; 60(5):585-9. PubMed ID: 991147
[TBL] [Abstract][Full Text] [Related]
3. Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up.
Dutcher JP; Wiernik PH; Markus S; Weinberg V; Schiffer CA; Harwood KV
Leukemia; 1988 Jul; 2(7):413-9. PubMed ID: 3393023
[TBL] [Abstract][Full Text] [Related]
4. Therapy in childhood acute nonlymphocytic leukemia (ANLL). Evolution of current concepts of chemotherapy.
Steuber CP
Am J Pediatr Hematol Oncol; 1981; 3(4):379-88. PubMed ID: 6174052
[TBL] [Abstract][Full Text] [Related]
5. Results of aggressive chemotherapy for acute nonlymphoblastic leukemia in adults.
Armitage JO; Burns CP; Dick FR; Aunan SB; Slymen DJ
Cancer Treat Rep; 1982 Nov; 66(11):1917-24. PubMed ID: 7139637
[TBL] [Abstract][Full Text] [Related]
6. Remission maintenance therapy in acute myelogenous leukemia.
Embury SH; Elias L; Heller PH; Hood CE; Greenberg PL; Schrier SL
West J Med; 1977 Apr; 126(4):267-72. PubMed ID: 266313
[TBL] [Abstract][Full Text] [Related]
7. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute nonlymphocytic leukemia (ANLL) in elderly patients. Results of a multicentric study.
Mandelli F; Amadori S; Fabiani F; Grignani F; Liso V; Martelli M; Neri A; Petti MC; Tonato M
Haematologica; 1979 Jun; 64(3):331-8. PubMed ID: 113301
[No Abstract] [Full Text] [Related]
9. Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia.
Cassileth PA; Kahn SB; Silber R; Weiler C
Cancer Clin Trials; 1981; 4(2):125-8. PubMed ID: 7249250
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of acute leukemia in adults with cytosine arabinoside and thioguanine].
Kotlarek-Haus S; Lawińska B; Kuliszkiewicz-Janus M
Acta Haematol Pol; 1978; 9(4):237-42. PubMed ID: 735711
[TBL] [Abstract][Full Text] [Related]
11. Remission-induction regimens in acute nonlymphocytic leukemia.
Brennan DC; Lewis JP
West J Med; 1980 Oct; 133(4):279-88. PubMed ID: 7347042
[TBL] [Abstract][Full Text] [Related]
12. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
13. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute nonlymphocytic leukemia in elderly patients: a prospective study of intensive chemotherapy.
Peterson BA; Bloomfield CD
Cancer; 1977 Aug; 40(2):647-52. PubMed ID: 890652
[TBL] [Abstract][Full Text] [Related]
15. Absence of the influence of age on remission rate and duration of remission in a group of thirty-four patients with acute myeloid leukaemia.
De Vries EG; Mulder NH; Houwen B; Haaxma-Reiche H; De Vries-Hospers HG
Neth J Med; 1980; 23(6):241-5. PubMed ID: 6936611
[No Abstract] [Full Text] [Related]
16. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
[TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free survival in acute nonlymphocytic leukemia.
Peterson BA; Bloomfield CD
Blood; 1981 Jun; 57(6):1144-7. PubMed ID: 6784795
[TBL] [Abstract][Full Text] [Related]
18. Treating acute nonlymphocytic leukemia.
Richert-Boe KE; Bagby GC
Geriatrics; 1978 Feb; 33(2):50-5. PubMed ID: 620934
[TBL] [Abstract][Full Text] [Related]
19. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults].
Kurita S; Ota K; Yamada K; Massaoka T; Uzuka Y; Ogawa N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2742-50. PubMed ID: 6508324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
